Georgia's Online Cancer Information Center

Find A Treatment Site

Atrium Health Navicent

The Peyton Anderson Cancer Center is a building located at 800 First Street, Macon, Georgia. The Services provided in the building are part of Atrium Health Navicent or they are private practitioners.

Visitors will find warm, friendly staff providing patient focused care.

At Atrium Health Navicent Everything about us is all about you.

Among the services you will find at The Peyton Anderson Cancer Center, Atrium Health Navicent are:

  • General Number                                                                            (478) 633-3000
  • PET/CT Center, Atrium Health Navicent                                        (478) 633-4738
  • Breast Care Center, Atrium Health Navicent                                 (478) 633-7020
  • Central Georgia Cancer Care                                                        (478) 743-7068
  • Infusion Services, Atrium Health Navicent                                    (478) 633-8811
  • Central Georgia Radiation Oncology                              &nbs

Treatment Sites in Georgia

Primary Location

Oncology Research, Atrium Health Navicent
777 Hemlock Street, MSC 123
(PACC 800 1st St, Ste 250)
Macon, GA 31201
478-633-3000 (p)
478-633-8894 (f)
www.Atriumhealth.org

driving directions


Central Georgia Cancer Care

800 First Street
Suite 410
Macon, 31201
478 633-2152 (p)
(478) 633-8894 (f)


driving directions

Clinical Trials in Georgia

A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type: Brain Tumor, Unknown Primary, Wilms Tumor

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type: Sarcoma, Unknown Primary

A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type: Leukemia
Study Coordinator: Oncology Research Nurse - 4786332152


Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Cancer Type: Germ Cell Tumor, Testicular Cancer
Study Coordinator: Oncology Research Nurse - 4786332152


Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type: Germ Cell Tumor, Testicular Cancer
Study Coordinator: Oncology Research Nurse - 4786332152


Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer, Unknown Primary
Study Coordinator: Oncology Research Nurse - (478)633-2152


Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Cancer Type: Leukemia
Study Coordinator: Oncology Research Nurse - 4786332152


Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Cancer Type: Leukemia, Testicular Cancer
Study Coordinator: Oncology Research Nurse - 4786332152


Project: Every Child for Younger Patients with Cancer
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Neuroendocrine Tumor, Solid Tumor, Unknown Primary
Study Coordinator: Oncology Research Nurse - 4786332152


Study of Renal Tumors in Pediatric Patients
Cancer Type: Kidney Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents with Cancer
Cancer Type: Solid Tumor, Unknown Primary
Study Coordinator: Oncology Research Nurse - 4786332152
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.